Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant And Placebo Controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of ACC-001 With QS-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease .

Next Previous
Search
Trial Profile

A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant And Placebo Controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of ACC-001 With QS-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease .

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QS 21 (Primary) ; Vanutide cridificar (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Pfizer

Most Recent Events

  • 18 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
  • 29 Aug 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov record.
  • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top